气喘为气管道的慢性发炎性疾病，急性发作严重时可能会造成呼吸衰竭，甚至导致生命危险。本篇研究目的为评估自国人体内筛选出之乳双岐杆菌GKK2改善OVA诱导之小鼠过敏情形及有效调节相关过敏因子。实验将Balb/c小鼠分为四组：生理食盐水组、OVA诱导气喘组、OVA诱导小鼠给予GKK2-100组(0.123 mg/day/kg)及OVA诱导小鼠给予GKK2-300组(0.41 mg/day/kg)。实验结果显示，OVA致敏小鼠经给予乳双岐杆菌GKK2低高两剂量组后，其呼吸道阻力、嗜酸性球(eosinophil)及OVA特异性IgE皆较OVA诱导气喘小鼠组别显著降低许多。在IFN- γ及IgG2a方面，给予乳双岐杆菌GKK2，则能有效增加致敏小鼠体内IFN- γ及IgG2a的含量，降低过敏反应。
Asthma is a chronic bronchitis that can cause respiratory failure and even lead to life-threatening in severe conditions. The present study is to evaluate Bifidobacterium lactis GKK2 ability in improving allergic problems and regulating related allergic factors in a mouse model of OVA-allergic asthma. Balb/c mice were divided into four groups as follows: control group, OVA-allergic asthma group, OVA-allergic asthma with GKK2-100 group (0.123 mg/day/kg) and OVA-allergic asthma with GKK2-300 group (0.41 mg/day/kg). Results showed that after OVA-allergic asthma mice were given both doses of B. lactis GKK2, their airway resistance, eosinophil, and OVA-specific IgE were significantly lower than those of OVA-induced asthmatic mice. In the IFN- γ and IgG2a, administration of B. lactis GKK2 can also effectively increase the content of IFN- γ and IgG2a in OVA-induced asthmatic mice and reduce allergic reactions.